KAPA (Kairos Pharma) Receivables Turnover : 0.00 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kairos Pharma Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Kairos Pharma's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Kairos Pharma's average Accounts Receivable for the three months ended in Dec. 2024 was $0.00 Mil.

Kairos Pharma Receivables Turnover Historical Data

The historical data trend for Kairos Pharma's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kairos Pharma Receivables Turnover Chart

Kairos Pharma Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Receivables Turnover

Kairos Pharma Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Receivables Turnover	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of Kairos Pharma's Receivables Turnover

For the Biotechnology subindustry, Kairos Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kairos Pharma's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kairos Pharma's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Kairos Pharma's Receivables Turnover falls into.

Save Embed

;

Save Embed

;

Kairos Pharma Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Kairos Pharma's Receivables Turnover for the fiscal year that ended in Dec. 2024 is calculated as

	Receivables Turnover (A: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2024 )	/ (	(Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Kairos Pharma's Receivables Turnover for the quarter that ended in Dec. 2024 is calculated as

	Receivables Turnover (Q: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2024 )	/ (	(Accounts Receivable (Q: Sep. 2024 )	+	Accounts Receivable (Q: Dec. 2024 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Kairos Pharma (AMEX:KAPA) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Kairos Pharma Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Kairos Pharma's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Kairos Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kairos Pharma Ltd (AMEX:KAPA) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

2355 Westwood Boulevard, 139, Los Angeles, CA, USA, 90064

Website

https://kairospharma.com

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.